Related Experiment Video
Updated: Feb 6, 2026

Modified Experimental Conditions for Noise-Induced Hearing Loss in Mice and Assessment of Hearing Function and Outer Hair Cell Damage
Published on: February 10, 2023
Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss
Abstract:
There are currently no FDA-approved therapies to prevent the hearing loss associated with the usage of cisplatin in chemotherapeutic regimens. We recently demonstrated that the pharmacologic inhibition with kenpaullone or genetic deletion of CDK2 preserved hearing function in animal models treated with cisplatin, which suggests that CDK2 is a promising therapeutic target to prevent cisplatin-induced ototoxicity. In this study, we identified two lead compounds, AT7519 and AZD5438, from a focused library screen of 187 CDK2 inhibitors, performed in an immortalized cell line derived from neonatal mouse cochleae treated with cisplatin. Moreover, we screened 36 analogues of AT7519 and identified analogue 7, which exhibited an improved therapeutic index. When delivered locally, analogue 7 and AZD5438 both provided significant protection against cisplatin-induced ototoxicity in mice. Thus, we have identified two additional compounds that prevent cisplatin-induced ototoxicity in vivo and provided further evidence that CDK2 is a druggable target for treating cisplatin-induced ototoxicity.
Insights
New compounds AT7519 and AZD5438 show promise in preventing cisplatin-induced hearing loss. These CDK2 inhibitors offer potential therapeutic strategies for chemotherapy patients experiencing ototoxicity.
Area of Science:
- Ototoxicity research
- Pharmacology
- Cancer therapeutics
Background:
- Cisplatin chemotherapy can cause irreversible hearing loss (ototoxicity).
- Currently, no FDA-approved therapies exist to prevent this side effect.
- Cyclin-dependent kinase 2 (CDK2) has been identified as a potential therapeutic target.
Purpose of the Study:
- To identify novel compounds that inhibit CDK2 and prevent cisplatin-induced ototoxicity.
- To evaluate the efficacy of identified compounds in preclinical models.
Main Methods:
- Screening of 187 CDK2 inhibitors in a cisplatin-treated mouse cochlear cell line.
- Focused screening of AT7519 analogues.
- In vivo testing of lead compounds (AZD5438 and analogue 7) in mice.
Main Results:
- Two lead compounds, AT7519 and AZD5438, were identified.
- Analogue 7, derived from AT7519, demonstrated an improved therapeutic index.
- Both analogue 7 and AZD5438 provided significant protection against cisplatin-induced ototoxicity in mice.
Conclusions:
- AT7519 and AZD5438 are effective in preventing cisplatin-induced ototoxicity in vivo.
- These findings further validate CDK2 as a druggable target for mitigating chemotherapy-related hearing loss.
Related Concept Videos
Hearing
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Line Loss
Line loss impacts power delivery efficiency in a balanced three-phase circuit. The symmetry in such a circuit simplifies the...
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
Cancer Prevention
Some...
Sustainable Development

